ÂÜÀòÂÒÂ×

Grant Bogle joined Epizyme in August 2021 as President and Chief Executive Officer and has served on the Epizyme board of directors since September 2019. Prior to joining Epizyme, Grant served as senior vice president and chief commercial officer of TESARO, where he oversaw the build-up of the US commercial organization and led the launch of two products, including ZEJULA® (niraparib) for ovarian cancer in the US. With more than 40 years of experience across the healthcare industry, Grant held several senior leadership positions at McKesson Specialty Health (formerly US Oncology) where he led numerous businesses that supported oncology-focused companies to engage, educate and support oncologists and patients to access and appropriately utilize their medications. These businesses included data and informatics, health economics and outcomes research, reimbursement hub services and the US Oncology clinical research business units. Before that, he was senior vice president of sales and marketing at Millennium Pharmaceuticals, leading the commercialization of VELCADE® (bortezomib). Earlier in his career, Mr. Bogle held various senior commercial roles with ViaCell, Inc., Roche Pharmaceuticals, Knoll Pharmaceuticals and DuPont Pharmaceuticals. He began his career at American Critical Care, a division of American Hospital Supply Corporation.

Mr. Bogle holds a B.A. in economics from Dartmouth College and an MBA from Columbia University’s Columbia School of Business. When not focused on Epizyme, you will find Grant and his wife in the Berkshires, cycling through beautiful countryside on bikes, participating in water sports and enjoying family and friends.